Endo Pharmaceuticals Inc. has launched Natesto testosterone nasal gel commercially. The company says it is the first and only nasal gel for testosterone replacement therapy in adult males diagnosed with hypogonadism.  Natesto was approved by the U.S. Food and Drug Administration (FDA) in May 2014 for replacement therapy in adult men with conditions associated with deficiency or absence of endogenous testosterone, including primary hypogonadism—congenital or acquired—or hypogonadotropic hypogo...